$1.23
-0.01 (-0.81%)
Open$1.25
Previous Close$1.24
Day High$1.26
Day Low$1.22
52W High$3.54
52W Low$1.25
Volume—
Avg Volume1.38M
Market Cap134.01M
P/E Ratio—
EPS$-1.08
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+556.9% upside
Current
$1.23
$1.23
Target
$8.08
$8.08
$6.79
$8.08 avg
$13.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.41M | 13.34M | 54.83M |
| Net Income | -164,769,207 | -159,368,389 | 10.00M |
| Profit Margin | -1,327.4% | -1,261.0% | 18.2% |
| EBITDA | -171,147,638 | -174,734,289 | 16.80M |
| Free Cash Flow | — | — | 9.93M |
| Rev Growth | -7.0% | -7.0% | -2.4% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |